← All trials
NCT04355052
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 11, 2020
- Primary completion
- Oct 11, 2020
- Completion date
- Dec 11, 2020
- First posted
- Apr 21, 2020
- Last posted
- Apr 21, 2020
- Enrollment
- 250
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tel Aviv UniversityLead sponsor
- Tel Aviv UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.